1 / 24

BRIC Health Systems and Big Pharma: Strategic Policy Issues

This research paper explores strategic issues in BRIC nations' health systems and pharmaceutical sectors, analyzing mortality rates, disease burdens, healthcare expenditures, and market trends. It provides insights into the challenges faced by these countries in tackling major health issues.

aclayton
Download Presentation

BRIC Health Systems and Big Pharma: Strategic Policy Issues

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BRIC HealthSystems and Big Pharma: Strategic Policy Issues Guilhem Fabre and Victor Rodwin Université Paul Valéry Montpelier 3, Wagner School of Public Service New York University June 5, 2017

  2. Table 1. Age standardized mortality rates by cause (per 100 000 population) in BRIC nations Source: World Health Statistics 2015

  3. Table 2. Burden of disease due to HIV/AIDS in the BRICS countries Sources: Avert.org, WHO Global Health Observatory Data Repository

  4. Table 3. Burden of disease due to Tuberculosis in the BRICS countries

  5. Cancer Mortality Estimates: BRIC Nations, France and US, 2012 Source: Cancer Research UK – Worldwide Cancer Mortality Statistics

  6. Table 4. Probability of dying between ages of 30 and 70 from cardiovascular disease, cancer, diabetes, or chronic respiratory (%) in 2015 and 2010 (both sexes) Sources: WHO Global Health Observatory Data Repository

  7. Table 5: Health Expenditures in BRIC Nations

  8. IMS HEALTH. PHARMERGING MARKETS - PICKING A PATHWAY TO SUCCESS

  9. Table 6. Pharmerging and Mature Markets IMS HEALTH. PHARMERGING MARKETS - PICKING A PATHWAY TO SUCCESS

  10. Table 7. Pharmerging Markets, 2008-2017 IMS HEALTH. PHARMERGING MARKETS - PICKING A PATHWAY TO SUCCESS

  11. Table 8. China Leads the way

  12. Watt, N. F., Gomez, E. J., & McKee, M. (2013). Global health in foreign policy—and foreign policy in health? Evidence from the BRICS. Health Policy and Planning, N/A, 1-11. 10.1093/heapol/czt063

  13. Table 9. BRIC Pharmaceutical Market

  14. Brazil EMI, Brazilian Pharmaceutical sector, Dec. 2013

  15. Structure of Russian Pharmaceutical Market Deloitte, Development Trends and Practical Aspects of the Russian Pharmaceutical Industry, 2015

  16. Chitour, Hind-Louiza, Big Pharma in China – the Driving Forces behind Their Success –A qualitative Analysis. Chinese Studies (2)4, 2013.

  17. China Hsaio W., Li M., Zhang S. Universal Health Coverage: The Case of China. 2015 Working Paper, UNRISD

More Related